Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Experimental drug ameliorates symptoms of neurodegenerative brain disease in mice

09.10.2015

In cooperation with colleagues in Munich and Göttingen, researchers at the German Center for Neurodegenerative Diseases (DZNE) in Bonn have analyzed a novel substance that could serve as a prototype for the development of drugs to treat Alzheimers and other brain diseases. Known as anle138b, this substance ameliorated disease symptoms in mice and improved their cognition. The scientists report on these findings in the journal Acta Neuropathologica.

“We have found that this substance prevents the aggregation of tau proteins. This aggregation is typical of Alzheimer’s and other brain diseases classified as tauopathies,” explains DZNE researcher Dr. Martin Fuhrmann, who worked on this study with colleagues at the Ludwig-Maximilians-University Munich (LMU) and the Max Planck Institute for Biophysical Chemistry in Göttingen. “Treatment with anle138b could be one way of intervening in the progress of the disease.”


A look inside of a mouse brain: tau proteins are enriched in the magenta areas. They are particularly highly concentrated in some of the neurons (light spots). The dendrites (filamentous processes

DZNE/Jens Wagner

Effect on pathologically altered protein

Under normal conditions, the tau proteins stabilize the microtubules that are part of the cytoskeleton of neurons in the brain. The cytoskeleton gives the cell mechanical stability and serves as a transport network for substances essential to the cell’s metabolism.

However, in cases of Alzheimer’s disease and other tauopathies, the tau proteins have undergone an alteration: they become detached from microtubules and aggregate into filamentous tau-tangles. As a result, the microtubules’ function and the cell’s metabolism are impaired, which eventually leads to neuronal death.

Amelioration of disease symptoms

“The experiments were inspired by our earlier studies that showed high efficacy against the formation of pathological protein aggregation,” says Prof. Armin Giese from the Center for Neuropathology and Prion Research at the LMU Munich. “These led us to suspect that anle138b could prevent the aggregation of tau proteins.”

The mice treated by the scientists had a genetic defect that caused them to display various characteristics typical of tauopathies, the same as those that manifest in humans. Besides aggregation of tau proteins, these include cognitive disorders and a shorter life expectancy. It turned out that the substance, which was administered in the mice’s food, not only works at molecular level but also influences disease symptoms. “The mice’s working memory skills improved and they lived longer,” says Fuhrmann. The scientists also found that the treated mice had less neuron loss than those that had not been treated.

Disease development apparently slowed

“In contrast to other substances Anle138b is orally available because of its chemical and metabolic characteristics. Therefore, it stays for hours within the body and targets specifically protein aggregation”, says Prof. Christian Griesinger from the Max Planck Institute for Biophysical Chemistry, whose team synthesized the substance.

“Anle138b cannot stop the disease from progressing in the animal model, but it seems to slow it down,” says DZNE scientist Fuhrmann. “Anle138b is therefore a possible starting point for the development of drugs that prevent the aggregation of tau proteins.” However, the results from mice are not directly transferable to human. “The efficacy and tolerance for humans have to be tested in demanding clinical trials. Even with an optimistic perspective it will take years until a treatment for patients might be available.” Currently, a joint venture of LMU and MPG develops the drug Anle138b further.

Original publication
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
Jens Wagner, Sybille Krauss, Song Shi, Sergey Ryazanov, Julia Steffen, Carolin Miklitz, Andrei Leonov, Alexander Kleinknecht, Bettina Göricke, Jochen H. Weishaupt, Daniel Weckbecker, Anne M. Reiner, Wolfgang Zinth, Johannes Levin, Dan Ehninger, Stefan Remy, Hans A. Kretzschmar, Christian Griesinger, Armin Giese, Martin Fuhrmann.
Acta Neuropathologica, DOI:10.1007/s00401-015-1483-3.

Weitere Informationen:

https://www.dzne.de/en/about-us/public-relations/meldungen/2015/press-release-no... Link to release
http://link.springer.com/article/10.1007%2Fs00401-015-1483-3 Link to paper

Dr. Marcus Neitzert | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Navigational view of the brain thanks to powerful X-rays
18.10.2017 | Georgia Institute of Technology

nachricht Separating methane and CO2 will become more efficient
18.10.2017 | KU Leuven

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Osaka university researchers make the slipperiest surfaces adhesive

18.10.2017 | Materials Sciences

Space radiation won't stop NASA's human exploration

18.10.2017 | Physics and Astronomy

Los Alamos researchers and supercomputers help interpret the latest LIGO findings

18.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>